5-HT, 5-hydroxytryptamine (serotonin); ADH, antidiuretic hormone; AEA, N-arachidonoylethanolamine (anandamide); ANOVA, one-way analysis of variance; ARRIVE, animal research: reporting of in vivo experiments (guidelines); ARV, antiretroviral; Ach, acetylcholine; CB, cannabinoid; CNS, central nervous system; CPP, conditioned place preference; Cocaine; DA, dopamine; DAT, dopamine transporter; DOA's, drug(s) of abuse; ECS, endocannabinoid system; EFV, efavirenz; ELISA, enzyme-linked immunosorbent assay; Efavirenz; GABA, gamma-aminobutyric acid; Glu, glutamate; HIV, human immunodeficiency virus; HNS, hypothalamic neurohypophysial system; HPA, hypothalamic-pituitary-adrenal (axis); IP, intraperitoneal; IV, intravenous; M, muscarinic; MA, methamphetamine; MAO, monoamine oxidase; Methamphetamine; NAc, nucleus accumbens; NE, norepinephrine; NO, nitric oxide; NPAE, neuropsychiatric adverse effect; OT, oxytocin; OTR, oxytocin receptor; Oxytocin; PND, postnatal day; PVN, paraventricular nucleus; SC, subcutaneous; SD, Sprague Dawley (rat); SEM, standard error of the mean; SERT, serotonin transporter; SON, supraoptic nucleus; VMAT, vesicular monoamine transporter; VP, vasopressin; VPR, vasopressin receptor; Vasopressin; cART, combined antiretroviral therapy; ∆9-THC, delta-9-tetrahydrocannabinol; ∆9-tetrahydrocannabinol